Rejected at 9:29 p.m. Oct, 31, 2023 ] by dollajas
Author: harmorgmed
Related Note: 1488855052316
Rationale for change

prompts for two answers

Rejection reason

since this is a family of cards i will want them to have the same wording despite the # of answers

Text Text
Extra
COX-2 is more resistant to inhibition than COX-1, so higher doses of aspirin are required to achieve the antipyretic, analgesic, and finally anti-inflammatory effects

- Low dose (below 300 mg/day): inhibition of platelet aggregation
- Intermediate dose (300-2400 mg/day): antipyretic and analgesic effect
- High dose (2400-4000 mg/day): anti-inflammatory effect

Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy


Watch NSAIDs
Sketchy 2


Watch Postoperative Surgical Fevers
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize





Physeo

Bootcamp


Watch associated Bootcamp video - Pharmacology : NASIDs
OME

Additional Resources
One by one
Empty field
!AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::#OME::PreClinical::Musculoskeletal !AK_UpdateTags::AnKing_Image::Aiman::Arachidonic_Acid_Pathway #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::^Systems::Musculoskeletal::Pharmacology #AK_Step1_v12::#Pixorize::03_Pharmacology::13_Musculoskeletal_Pharm::01_Aspirin #AK_Step1_v12::#Pixorize::03_Pharmacology::13_Musculoskeletal_Pharm::05_NSAIDs #PANCE::CARDIO::coronary_artery_disease #PANCE::EOR::IM #AK_Step2_v12::#SketchySurgery::01_Preoperative_&_Postoperative_Surgical_Considerations::02_Postoperative::01_Postoperative_Surgical_Fevers #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#Bootcamp::Musculoskeletal::15_Pharmacology::03_NSAIDs #AK_Step1_v12::#Physeo::09_Pharm::09_Musculoskeletal::04_NSAIDs #AK_Step1_v12::#B&B::11_Hematology::01_Hemostasis::06_Antiplatelet_Drugs::Extra #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::03_Anti-inflammatory::01_NSAIDs #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::04_Antiplatelet_Drugs #AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#FirstAid::11_Musculoskeletal_Skin_and_Connective_Tissue::04_Pharm::03_Aspirin #AK_Step1_v12::#B&B::12_Immunology::03_Pharm::01_Glucocorticoids_and_NSAIDs #AK_Step1_v12::#Physeo::09_Pharm::09_Musculoskeletal::02_Aspirin #AK_Step1_v12::#AMBOSS::PiaW74